Earlier today, Moderna hosted its 2026 Analyst Day, providing updates on our business strategy, pipeline progress and future priorities.
Members of our executive team sat down to share additional insights into the key takeaways from Analyst Day and what’s ahead for Moderna.
Watch our latest IR Insights video below to hear more: modernatx.com/recapping-2026…
Today we outlined the next phase of growth at our 2026 Analyst Day, highlighting how more than a decade of investment in our mRNA platform has enabled the development of multiple modalities of mRNA medicines, each with the potential to create durable franchises.
We also provided updates on commercial growth, oncology pipeline progress, manufacturing readiness and mid-term financial objectives.
Read more: feeds.issuerdirect.com/news-…
Today we announced a publication in @JAMANetworkOpen of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE® (COVID-19 Vaccine, mRNA) and Comirnaty® (COVID-19 Vaccine, mRNA) among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season.
Read more: lnkd.in/eVS6kvA4
Earlier today, Moderna reported financial results for the third quarter of 2026. Jamey Mock, Chief Financial Officer, sat down for an episode of IR Insights to discuss our financial performance.
Watch the episode here: modernatx.com/third-quarter-…
Today we reported financial results and provided business updates for the third quarter of 2026.
Read more: feeds.issuerdirect.com/news-…
Today we announced that Health Canada has authorized mFLUSIVA® (Influenza mRNA vaccine; mRNA-1010) and mCOFLU® (Combined Influenza and COVID-19 mRNA vaccine; mRNA-1083) for adults 50 years of age and older.
Read more: feeds.issuerdirect.com/news-…
Today we announced that mRNA-1469, our investigational mRNA vaccine candidate against Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy study in the Democratic Republic of the Congo (DRC), supported by encouraging preclinical and Phase 1 clinical data.
Read more: accessnewswire.com/newsroom/…
Today we announced that initial clinical data from our ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana.
Read more: accessnewswire.com/newsroom/…
#ASH2026
With our partners at @Merck, we announced detailed results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized neoantigen therapy, in combination with pembrolizumab, in patients with completely resected stage IIB-IV melanoma.
Presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026, these findings offer important insights into the potential of individualized cancer treatment.
Read more: modernatx.com/recapping-the-…
Today we announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage IIB-IV) following complete resection.
These late-breaking results will be presented during a Presidential Symposium at the 2026 European Society for Medical Oncology (@myESMO) Congress.
Read more: feeds.issuerdirect.com/news-…
Today, we announced the addition of a Chief Operating Officer role to support the growing scale and diversification of our company.
Juan Andres will return to Moderna as Chief Operating Officer, effective October 5, 2026. In this role, he will help drive focus, prioritization and execution across the Company while leading our manufacturing organization. Juan previously spent nearly six years at Moderna, serving in several leadership roles before retiring from the Company in 2023.
Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, has decided to retire from Moderna. Since joining in 2022, Jerh has helped evolve our manufacturing footprint for an endemic vaccine market, advance our capabilities in the UK, Canada and Australia, and establish the manufacturing model to support intismeran autogene, our investigational individualized neoantigen therapy.
We’re pleased to welcome Juan back to Moderna and grateful to Jerh for his leadership and contributions.
feeds.issuerdirect.com/news-…
Today we announced that three abstracts on intismeran autogene, our investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (@myESMO) Congress 2026, which will be held October 23–27 in Madrid, Spain.
Read more: feeds.issuerdirect.com/news-…
#ESMO26
Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19.
Read more: feeds.issuerdirect.com/news-…
Along with our partners at @Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment in patients with completely resected Stage IIB-IV melanoma. This marks the first and only combination regimen to demonstrate a clinically meaningful improvement over pembrolizumab alone, a current standard-of-care for these patients.
In our latest IR Insights, members of our executive team sat down to reflect on what this means: modernatx.com/ir-insights-ph…
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Today we announced that the U.S. Food and Drug Administration has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee supporting mFLUSIVA for adults 50 years of age and older.
Read more: feeds.issuerdirect.com/news-…
Today we announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, our investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus disease.
Read more: feeds.issuerdirect.com/news-…
Today we reported financial results and provided business updates for the second quarter of 2026.
Read more: feeds.issuerdirect.com/news-…




















